Semaglutide

The World Health Organization has finally made its recommendations on using GLP-1 therapeutics for weight loss, though it remains to be seen whether it changes their status for prescribing or price. And scientists still have some concerns.

Scientists have failed to show that weight-loss wonder drug semaglutide can also slow the progress of Alzheimer's disease (AD), as two two-year clinical trials end in disappointment for patients, medical scientists and drugmaker Novo Nordisk.

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of cardiovascular events like heart attack and stroke.

While Ozempic and other drugs like it have proven effective in helping people lose weight, many gain it back when the injections stop. A new drug targets weight loss differently, leading to a more permanent fat-shedding solution.

A clinical trial has shown that Ozempic improves blood glucose levels and weight loss in overweight type 1 diabetics who use an automated insulin delivery system. It’s hoped this will lead to the approval of Ozempic for this patient population.